Bryxta 100 Injection 4 ml is a monoclonal antibody used to treat metastatic breast cancer, non-small cell lung cancer, kidney cancer, cervical cancer, epithelial ovarian, fallopian tube, or primary peritoneal cancer, cancer of colon and rectum. Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. Cancer can start in one region of the body and spread to other parts. This is referred to as metastasis. Bryxta 100 Injection 4 ml contains 'Bevacizumab' that works against vascular endothelial growth factor (VEGF) which is found on the lining of lymph and blood vessels. VEGF causes blood vessels to grow within tumours which provide oxygen and nutrients to the tumour. Inhibition of vascular endothelial growth factor limits the flow of oxygen and nutrients to the tumour, causing it to shrink or cease developing. Thus, it helps treat cancers. Bryxta 100 Injection 4 ml will be administered by a healthcare professional; do not self-administer. Based on your medical condition, your doctor will decide the dose and duration. In some cases, Bryxta 100 Injection 4 ml may cause loss of appetite, constipation, fever, nosebleeds, change in speech, and taste. The majority of these side effects do not require medical treatment and fade away with time. However, consult your doctor if the side effects persist or worsen Avoid taking Bryxta 100 Injection 4 ml if you are pregnant. Use effective contraception during the treatment and for 6months after the last dose. Bryxta 100 Injection 4 ml may cause sleepiness and fainting, so avoid driving while on treatment with Bryxta 100 Injection 4 ml. Do not breastfeed during the treatment and for 6months after the last dose of Bryxta 100 Injection 4 ml. Keep your doctor informed about your health condition and all the medicines you take to rule out any side effects.
Send Message